ORIC Stock Price, ORIC Pharmaceuticals Inc Quote, Chart

Market Summary

USD9.01+0.04

Delayedas of 14 May 2024, 11:48 am

0.45%

ORIC Stock Price

View Fullscreen

ORIC RSI Chart

ORIC Valuation

Market Cap

604.8M

Price/Earnings (Trailing)

-5.94

Price/Sales (Trailing)

10.5K

Price/Free Cashflow

-6.3

ORIC Price/Sales (Trailing)

ORIC Profitability

Return on Equity

-30.96%

Return on Assets

-29.01%

Free Cashflow Yield

-15.87%

ORIC Fundamentals

ORIC Revenue

Revenue (TTM)

60.0K

ORIC Earnings

Earnings (TTM)

-101.8M

Earnings Growth (Yr)

-4.45%

Earnings Growth (Qtr)

11.72%

Breaking Down ORIC Revenue

52 Week Range

4.919.79

(Low)(High)

Last 7 days

-4.3%

Last 30 days

-8.5%

Last 90 days

-20.5%

Trailing 12 Months

75.4%

How does ORIC drawdown profile look like?

ORIC Financial Health

Current Ratio

21.31

ORIC Investor Care

Shares Dilution (1Y)

49.52%

Diluted EPS (TTM)

-1.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	0	60.0K	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ORIC Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 06, 2024	chacko jacob	sold	-648,380	16.2095	-40,000	president and ceo
Feb 07, 2024	chacko jacob	sold	-320,186	12.295	-26,042	president and ceo
Feb 06, 2024	chacko jacob	sold	-169,160	12.1192	-13,958	president and ceo
Dec 15, 2023	piscitelli dominic	sold	-45,338	8.5835	-5,282	chief financial officer
Dec 15, 2023	chacko jacob	sold	-124,813	8.5847	-14,539	president and ceo
Dec 15, 2023	piscitelli dominic	sold	-	-	-14,042	chief financial officer
Dec 15, 2023	multani pratik s	acquired	-	-	14,042	chief medical officer
Dec 15, 2023	chacko jacob	acquired	-	-	38,667	president and ceo
Dec 15, 2023	multani pratik s	sold	-45,350	8.5859	-5,282	chief medical officer
Jul 11, 2023	chacko jacob	sold	-41,287	8.0076	-5,156	president and ceo

Which funds bought or sold ORIC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	LPL Financial LLC	added	2.9	49,488	141,488	-%
May 10, 2024	VANGUARD GROUP INC	added	27.95	18,905,100	39,628,300	-%
May 10, 2024	OSAIC HOLDINGS, INC.	added	12.4	1,563	3,863	-%
May 10, 2024	CITIGROUP INC	added	1,940	1,780,830	1,841,210	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	added	551	1,984,010	2,211,030	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	13.3	85,669	209,234	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	7,095	7,095	-%
May 10, 2024	AJOVista, LLC	sold off	-100	-40,084	-	-%
May 10, 2024	Clear Harbor Asset Management, LLC	new	-	188,980	188,980	0.02%
May 10, 2024	BlackRock Inc.	added	2.67	15,220,100	43,700,000	-%

Are Funds Buying or Selling ORIC?

Are funds buying ORIC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ORIC

No. of Funds

Unveiling ORIC Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	fmr llc	-	0	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	8.9%	6,275,210	SC 13G/A
Feb 13, 2024	prosight management, lp	2.9%	1,578,263	SC 13G/A
Feb 13, 2024	alkeon capital management llc	6.6%	3,604,096	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 07, 2024	blackrock inc.	4.5%	2,995,032	SC 13G/A
Feb 06, 2024	millennium management llc	0.0%	0	SC 13G/A
Feb 01, 2024	venrock healthcare capital partners iii, l.p.	6.6%	4,428,385	SC 13G
Jan 30, 2024	viking global investors lp	5.9%	4e+06	SC 13G
Jan 29, 2024	blackrock inc.	5.7%	3,095,648	SC 13G

Recent SEC filings of ORIC Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 06, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Mar 29, 2024	8-K	Current Report
Mar 29, 2024	S-8	Employee Benefits Plan
Mar 11, 2024	SC 13G/A	Major Ownership Report
Mar 11, 2024	10-K	Annual Report
Mar 11, 2024	8-K	Current Report

Peers (Alternatives to ORIC Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

ORIC Pharmaceuticals Inc News

Latest updates

ORIC Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)			(In Thousands)
Description	(%) Q/Q	2022Q3	2021Q3	2021Q2
Revenue	-	-	-	15.00
Operating Expenses	39.2%	25,694	18,456	21,057
S&GA Expenses	7.5%	5,971	5,557	5,540
Net Income	-34.7%	-24,829	-18,426	-21,009
Net Income Margin	-8.1%	-1.52	-1.40	-1.52
Free Cashflow	-59.4%	-19,721	-12,375	-16,349

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	39.2%	351	252	274	292	227	247	238	260	275	299	314	268	284	299	192	202	85.00	94.00	47.00
Current Assets	52.4%	324	213	232	268	193	210	199	234	239	241	293	265	280	297	189	199	80.00	90.00	44.00
Cash Equivalents	143.1%	57.00	23.00	26.00	104	59.00	67.00	29.00	49.00	113	226	241	170	104	78.00	62.00	197	79.00	89.00	43.00
Net PPE	-2.1%	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00
Liabilities	-20.7%	22.00	28.00	27.00	23.00	24.00	25.00	23.00	23.00	22.00	26.00	23.00	10.00	8.00	9.00	7.00	6.00	5.00	6.00	4.00
Current Liabilities	-25.7%	15.00	20.00	19.00	15.00	15.00	15.00	13.00	12.00	12.00	15.00	12.00	10.00	8.00	9.00	7.00	6.00	5.00	5.00	3.00
Shareholder's Equity	46.7%	329	224	247	269	203	222	215	237	253	273	292	258	276	290	184	195	-	-	-
Retained Earnings	-5.7%	-459	-434	-406	-381	-358	-334	-313	-288	-268	-245	-222	-203	-182	-166	-138	-112	-101	-92.69	-65.81
Additional Paid-In Capital	19.7%	789	659	654	650	561	558	530	527	522	518	514	462	459	456	323	308	3.00	3.00	1.00
Shares Outstanding	22.9%	67.00	55.00	55.00	55.00	45.00	45.00	39.00	39.00	39.00	39.00	37.00	37.00	-	-	-	-	-	-	-
Float	-	-	-	-	415	-	-	-	172	-	-	-	522	-	-	-	743	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-24.4%	-30,186	-24,270	-19,645	-21,145	-20,628	-15,329	-19,320	-17,776	-22,718	-16,284	-12,142	-16,214	-14,901	-17,825	-9,580	-9,584	-8,279	-7,148	-5,360	-5,494	-5,531
Share Based Compensation	26.4%	4,958	3,923	3,864	3,825	3,614	3,130	3,293	4,092	3,945	3,499	3,397	3,213	2,744	1,689	1,681	1,381	527	442	271	190	191
Cashflow From Investing	-395.1%	-61,868	20,963	-57,831	-19,313	12,778	28,300	-685	-46,203	-90,660	351	35,072	82,365	40,647	-91,256	-124,690	-202	189	-56.00	-219	-393	-100
Cashflow From Financing	27500.4%	125,030	453	31.00	85,174	-	24,793	1.00	415	16.00	813	48,586	-281	16.00	125,496	-341	126,986	-1,627	-61.00	5,698	49,923	15,264

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ORIC Income Statement

2024-03-31

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 21,960	$ 19,516
General and administrative	7,030	6,162
Total operating expenses	28,990	25,678
Loss from operations	(28,990)	(25,678)
Other income, net	3,979	1,733
Net loss	(25,011)	(23,945)
Other comprehensive income (loss):
Unrealized gain or loss on investments	(420)	792
Comprehensive loss	$ (25,431)	$ (23,153)
Net loss per share, basic	$ (0.37)	$ (0.53)
Net loss per share, diluted	$ (0.37)	$ (0.53)
Weighted-average shares outstanding, basic	67,349,551	45,090,166
Weighted-average shares outstanding, diluted	67,349,551	45,090,166

ORIC Balance Sheet

2024-03-31

BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 56,360	$ 23,384
Short-term investments	260,418	184,803
Prepaid expenses and other current assets	7,305	4,410
Total current assets	324,083	212,597
Long-term investments	14,694	26,852
Property and equipment, net	2,801	2,862
Other assets	9,208	9,696
Total assets	350,786	252,007
Current liabilities:
Accounts payable	2,988	944
Accrued liabilities	12,222	19,514
Total current liabilities	15,210	20,458
Other long-term liabilities	6,931	7,461
Total liabilities	22,141	27,919
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 67,420,338 and 54,865,553 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	7	6
Additional paid-in capital	788,738	658,751
Accumulated deficit	(459,938)	(434,927)
Accumulated other comprehensive (loss) income	(162)	258
Total stockholders' equity	328,645	224,088
Total liabilities and stockholders' equity	$ 350,786	$ 252,007

About ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

CEO	Dr. Jacob M. Chacko M.B.A., M.D.
WEBSITE	oricpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	89

ORIC Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for ORIC Pharmaceuticals Inc? What does ORIC stand for in stocks?

ORIC is the stock ticker symbol of ORIC Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ORIC Pharmaceuticals Inc (ORIC)?

As of Mon May 13 2024, market cap of ORIC Pharmaceuticals Inc is 604.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ORIC stock?

You can check ORIC's fair value in chart for subscribers.

What is the fair value of ORIC stock?

You can check ORIC's fair value in chart for subscribers. The fair value of ORIC Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ORIC Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ORIC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ORIC Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ORIC is over valued or under valued. Whether ORIC Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact ORIC Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORIC.

What is ORIC Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, ORIC's PE ratio (Price to Earnings) is -5.94 and Price to Sales (PS) ratio is 10.53 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORIC PE ratio will change depending on the future growth rate expectations of investors.